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932Objective: The Levitronix CentriMag (Levitronix LLC,Waltham,Mass) ventricular assist system is designed for
temporary left, right, or biventricular support. Advantages include ease of use, excellent reliability, and low
thrombosis risk,. which may allow wider application of short-term support and improved outcomes in patients
with cardiogenic shock. This multi-institutional study evaluated safety, effectiveness, and outcomes of the
CentriMag in patients with cardiogenic shock.
Methods: Thirty-eight patients were supported at 7 centers. Patients included 12 after cardiotomy, 14 after myo-
cardial infarction, and 12 with right ventricular failure after implantable left ventricular assist device placement.
Devices were implanted in left (n ¼ 8), right (n ¼ 12), or biventricular (n ¼ 18) configuration. Support was con-
tinued until recovery, transplantation, or implantation of long-term ventricular assist device.
Results:Mean support duration for the entire cohort (n¼ 38) was 13 days (1–60 days), with 47% of patients (18/
38) surviving 30 days after device removal. Mean CentriMag biventricular support (n¼ 18) duration was 15 days
(1–60 days), with 44% (8/18) surviving at 30 days. Mean CentriMag right ventricular support with a commer-
cially available left ventricular assist device (n¼ 12) duration was 14 days (1–29 days), with 58% (7/12) surviv-
ing at 30 days. Complications included bleeding (21%), infection (5%), respiratory failure (3%), hemolysis
(5%), and neurologic dysfunction (11%). There were no CentriMag or pump failures.
Conclusions: In this preliminary study, the CentriMag provided short-term support for patients with cardiogenic
shock with a low incidence of device-related complications and no device failures. (J Thorac Cardiovasc Surg
2011;141:932-9)Despite many advances in the management of patients with
acute heart failure, the outcomes for patients with refractory
acute cardiogenic shock remain disproportionately poor.1,2
Further, the vast majority of these patients are often in
hospitals that do not have access to advanced circulatory
support technologies or resources to optimally manage
these patients. Delay in referral to tertiary centers further
exacerbates the poor outcomes of this group of patients.
Clearly, there is a need for wider application of temporary
circulatory support for such patients. Questions remain as
to the ideal support system, the optimal duration of
temporary support, and the ideal timing to bridge these
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The Journal of Thoracic and Cardiovascular SurgThe Levitronix CentriMag (Levitronix LLC, Waltham,
Mass) ventricular assist system (VAS) was specifically de-
signed for treatment of patients with acute cardiogenic
shock of any etiology, including acute myocardial infarc-
tion, myocarditis, cardiotomy, and complications that may
arise in the cardiac catheterization laboratory.3 The Centri-
Mag generates as much as 10 L/min flow and is capable of
support for as long as 30 days with low risk of thromboem-
bolic complications. To date, the device has been used suc-
cessfully in more 3700 patients worldwide for such varied
indications as primary graft failure after heart transplanta-
tion, neonatal life support, and postcardiotomy cardiogenic
shock (PCCS). The device is unique in that it is driven with
a bearingless motor that enables the spinning component
within the pump to be magnetically levitated and rotated
without contact or wear. By eliminating bearings, shafts,
and seals associated with a conventional centrifugal
pump, the level of hemolysis and risk of thrombus accumu-
lation within the pump are greatly reduced, along with the
potential for adverse clinical sequelae. Further, the ease of
application allows the device to be used in centers that do
not have ventricular assist device (VAD) or transplant pro-
grams, and allows patients to be safely transported to ter-
tiary centers for advanced levels of care. The objective of
this report is to present preliminary clinical results that
support the safety and efficacy of the CentriMag pump
for patients with cardiogenic shock under a Food andery c April 2011
Abbreviations and Acronyms
ACT ¼ activated clotting time
BVAD ¼ biventricular assist device
ECMO ¼ extracorporeal membrane oxygenation
PCCS ¼ postcardiotomy cardiogenic shock
PMICS ¼ post–acute myocardial infarction
cardiogenic shock
LVAD ¼ left ventricular assist device
RVAD ¼ right ventricular assist device
VAD ¼ ventricular assist device
VAS ¼ ventricular assist system
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Device Description
The Levitronix CentriMag VAS is composed of a single-use centrifugal
blood pump, motor, drive console, backupmotor, backup drive console, and
cannulas (Figure 1).3 The Levitronix CentriMag VAS is different from other
devices in that it is designed to operate without mechanical bearings or seals.
This is possible because the motor levitates the rotor (the spinning compo-
nent of the device) magnetically, so that rotation may be achieved without
friction, regions of stasis, or component wear during operation. Eliminating
bearings, regions of stasis, component wear, friction, and the sources of
thermal damage reduces hemolysis and the risk of thrombus formation
within the pump. The design is based on bearingless motor technology,
which combines drive, magnetic bearing, and pump rotor functions into
a single unit that has no valves, seals, mechanical bearings, or moving parts
aside from the magnetically levitated rotor. The system is capable of oper-
ating across a range of speeds from 500 to 5500 rpm, generating flows as
great as 10 L/min under normal physiologic conditions. All system compo-
nents, with the exception of the single-use blood pump, are intended for
reuse on multiple patients.
For support, 22FMedtronic (Medtronic, Inc, Minneapolis, Minn) arterial
and 32F Edwards Lifesciences (Edwards Lifesciences, Irvine, Calif) venous
cannulas were used. For right ventricular (RVAD) support, the VAD inflow
cannula was positioned in the right atrial appendage and the outflow cannula
in the pulmonary artery. For left ventricular (LVAD) support, the left atrial
inflow cannula was inserted into the interatrial septal groove, adjacent to the
right superior pulmonary vein, with the outflow cannula in the ascending
aorta. Intraoperative transesophageal echocardiography was used to confirm
cannula positioning, absence of a patent foramen ovale, and adequate vol-
ume for support. Cannulas were secured with dual, pledgeted purse-string
sutures. During weaning and assessment of ventricular function, anticoagu-
lation was monitored and adjusted to reduce the risk of thrombosis forma-
tion during periods of reduced VAD flow. Anticoagulation varied
according to the needs and condition of each patient. In general, activated
clotting time (ACT) was checked before reduction of VAD flow for wean-
ing, and additional heparin was administered if the ACT was less than 200
seconds. ACT was rechecked during weaning; if necessary, additional
heparin was administered to maintain an ACT longer than 200 seconds.Study Description and Clinical Implementation
Two parallel Food and Drug Administration–approved pilot trials were
conducted in the United States to evaluate safety and effectiveness of the
CentriMag VAS for short-term circulatory support. A total of 38 patientsThe Journal of Thoracic and Cawere enrolled in these trials as of March 2009. All participating institutions
obtained institutional review board approval before study initiation. In-
formed consent was obtained from all subjects. A summary of each trial
is provided here.
Cardiogenic shock pilot trial. This was a nonrandomized, multi-
center pilot study to evaluate the use of the CentriMag system for as long as
14 days when used as either an LVAD or a biventricular assist device
(BVAD) to treat patients in cardiogenic shock. Two groups of patients
were evaluated: (1) patients with PCCS, and 2) patients with post–acute
myocardial infarction cardiogenic shock (PMICS). No control population
was used in this study. The intent was to maintain each patient on mechan-
ical circulatory support until the patient recovered, underwent transplanta-
tion or was weaned onto a long-term VAD. All surviving patients were
monitored as long as 6 months after support. For the treatment to be consid-
ered a success, patients needed to survive 30 days after support, to trans-
plant, or to implantation of a long-term VAD.
Twenty-six patients were enrolled into the cardiogenic shock pilot trial;
of these, 18 patients were implanted with both a CentriMag LVAD and
a CentriMag RVAD for as a BVAD. The remaining 8 patients were im-
planted with a CentriMag LVAD only. Twelve subjects were enrolled in
the PCCS arm, and 14 subjects were enrolled in the PMICS arm.
Use of CentriMag RVAD after implantation of a com-
mercial LVAD. This trial was a nonrandomized, multicenter pilot
study to evaluate the use of the CentriMag System for as long as 14 days
as an RVAD after implantation of a commercially available LVAD. Patients
were enrolled into this study either intraoperatively after unsuccessful wean-
ing from cardiopulmonary bypass or postoperatively for hemodynamic de-
compensation. For those patients enrolled postoperatively, enrollment had
to occur within 24 hours of the original surgery. No control group was
used. Similar to the cardiogenic shock trial, the intent was to maintain the
patient on mechanical circulatory support until the patient recovered, re-
ceived a transplant, or was transitioned to a long-term RVAD. For the treat-
ment to be considered a success, patients needed to survive 30 days after
weaning, to heart transplant, or to long-term RVAD transition.
Assessment of safety and efficacy. Baseline hemodynamic and
laboratory measurements were obtained before initiation of left, right or
biventricular support with the CentriMag VAD, depending on patient
requirements. Daily assessments were made of end-organ function, hemo-
dynamics, and neurologic status. Patients were followed up until discharge
and evaluated at 30 days and 6 months after device removal. Photography
and gross examination of the pump, cannulas, and connectors were
performed at pump removal.
The following parameters were studied: (1) hemodynamics before, dur-
ing, and after device support; (2) changes in hemodynamics during support;
(3) end-organ function before, during, and after device support; (4) changes
in end-organ function during support (5) CentriMag device–related adverse
effects; and (6) 30-day survival after device removal.
Adverse Events
The following adverse events, regardless of their relationship to the de-
vice, were documented.
Infection. Any infection diagnosed during the period of VAS support
was classified as device related unless the infection had been diagnosed
and any organisms cultured before initiation of VAS support.
Bleeding. Bleeding was defined as blood loss resulting in either surgical
exploration or blood transfusion requiring more than 3 units of packed red
blood cells within a 24-hour period. Bleeding was classified as device
related if it occurred from a VAS cannula attachment site.
Respiratory failure. Respiratory failure was defined as continued
ventilator support for more than 3 days after implantation or subsequent re-
intubation or tracheostomy for respiratory distress. Respiratory failure was
classified as device related if (1) respiratory dysfunction continued beyond
the first 5 days after device insertion, (2) reintubation or tracheostomy wasrdiovascular Surgery c Volume 141, Number 4 933
FIGURE 1. Levitronix CentriMag ventricular assist system (Levitronix LLC,Waltham, Mass). A, Single-use blood pump. B, Assembled device, consisting
of bearingless motor supporting pump. C, Portable primary drive console.
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a device-related thrombotic vascular complication.
Cardiac tamponade. Cardiac tamponade was determined according
to clinical examination and cardiac echocardiography.
Hepatic dysfunction. Hepatic dysfunction was defined as an in-
crease to 3 times baseline values in any 2 of the following parameters: total
bilirubin, serum alanine transaminase, serum aspartate transaminase, or
lactate dehydrogenase after the third postoperative day.
Renal failure. Renal failure was defined as a greater than 3-fold in-
crease in creatinine from baseline or a creatinine value greater than 6 mg/
dL after the first postoperative day, not present before implantation and
requiring hemodialysis or hemofiltration.
Neurologic status. Neurologic status was ascertained according to
the Glasgow Coma Scale and National Institutes of Health stroke scale.
Hemolysis. Hemolysis was defined as 2 consecutive samples within
24 hours in which plasma free hemoglobin was more than 40 mg/dL.
RESULTS
Results are presented for (1) the combined cohort of pa-
tients enrolled in both the cardiogenic shock and RVAD af-
ter implantation of a commercial LVAD studies (n¼ 38), (2)TABLE 1. Demographic characteristics of study populations
Cardiogenic shock protocol RVAD after
commercial
LVAD protocol
(n ¼ 12)
After
cardiotomy
(n ¼ 12)
After
acute MI
(n ¼ 14)
Combined
cohort
(n ¼ 38)
Age (y)
Mean  SD 58  12.3 60  11.4 55  14.3 58  12.4
Range 33–73 30–74 32–75 30–75
Sex (no.)
Male 5 (42%) 10 (71%) 8 (67%) 23 (61%)
Female 7 (58%) 4 (29%) 4 (33%) 15 (39%)
Height (cm)
Mean  SD 167  11.0 173  10.5 173  11.3 171  11.0
Range 152–185 147–185 155–192 147–192
Weight (kg)
Mean  SD 77  14.1 88  19.3 88  21.2 84  18.6
Range 55–99 48–117 61–128 48–128
Body surface area (m2)
Mean  SD 1.87  0.2 2.00  0.3 2.07  0.3 1.98  0.3
Range 1.59–2.12 1.40–2.33 1.70–2.55 1.40–2.55
MI,Myocardial infarction; RVAD, right ventricular support device; LVAD, left ventric-
ular assist device.
934 The Journal of Thoracic and Cardiovascular Surgpatients enrolled in the cardiogenic shock trial for the indica-
tions of PCCS (n ¼ 12) and PMICS (n ¼ 14), (3) patients
enrolled in the cardiogenic shock trial supported with Centri-
Mag BVAD (n¼ 18) or LVAD (n ¼ 8), and (4) patients en-
rolled in the RVAD after implantation of a commercial
LVAD study (n ¼ 12).
Demographic Characteristics
Overall patient demographic characteristics are presented
in Table 1. Patient demographic characteristics in the cardio-
genic shock trial subdivided by type of support (LVAD vs
BVAD) are presented in Table 2. Mean age of patients in
the entire cohort was 58 years (30–75 years). Mean age of
patients with in the PCCS group was 58 years (33–73 years),
and that in the PMICS group was 60 years (30–74 years). Of
the 12 patients in the PCCS group, 5 received BVADs and 7
received only LVADs. Of the 14 patients in the PMICS
group, 13 received BVADs and 1 received LVAD alone.
Most patients in the PCCS group had undergone coronary
artery bypass grafting; other procedures included ventricular
septal defect repair, valve replacement, and failed cardiac
transplant. In the PCCS group, left-sided inflow cannulation
sites included the left atrium (n¼ 8) and left ventricular apexTABLE 2. Demographic characteristics of cardiogenic shock groups
BVAD (n ¼ 18) LVAD (n ¼ 8) Total (n ¼ 26)
Age (y)
Mean  SD 58  12.6 62  8.9 59  11.6
Range 30–74 49–73 30–74
Sex
Male 12 (67%) 3 (37%) 15 (58%)
Female 6 (33%) 5 (63%) 11 (42%)
Height (cm)
Mean  SD 172  11.2 165  9.1 170  10.9
Range 147–185 152–175 147–185
Weight (kg)
Mean  SD 84  19.1 81  14.5 83  17.6
Range 48–117 60–99 48–117
Body surface area (m2)
Mean  SD 1.96  0.3 1.90  0.2 1.94  0.2
Range 1.40–2.33 1.60–2.11 1.40–2.33
BVAD, Biventricular assist device; LVAD, left ventricular assist device.
ery c April 2011
FIGURE 2. Thirty-day survival. RVAD, Right ventricular assist device;
PCCS, postcardiotomy cardiogenic shock; MI, myocardial infarction.
TABLE 3. Survival by group
30 d Discharge 6 mo
All (n ¼ 38) 18 (47%) 16 (42%) 12 (32%)
RVAD (n ¼ 12) 7 (58%) 5 (42%) 4 (33%)
PMICS (n ¼ 14) 7 (50%) 7 (50%) 6 (43%)
PCCS (n ¼ 12) 4 (33%) 4 (33%) 2 (17%)
LVAD (n ¼ 8) 3 (38%) 2 (25%) 2 (25%)
BVAD (n ¼ 18) 8 (44%) 8 (44%) 6 (33%)
All times are measured from device removal; all data are numbers of patients with per-
centages. RVAD, Right ventricular assist device; PMICS, post–acute myocardial in-
farction cardiogenic shock; PCCS, postcardiotomy cardiogenic shock; LVAD, left
ventricular assist device; BVAD, biventricular assist device.
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sites included the left ventricular apex (n ¼ 10) and the
left atrium (N¼3). The ascending aorta was used as the out-
flow cannulation site in all patients receiving left-sided Cen-
triMag LVAD support.
Clinical and Hemodynamic Outcomes
Overall and subgroup 30-day postexplant survivals, sur-
vivals to discharge, and 6-month survivals are shown in
Figure 2 and Table 3. The mean duration of support for
the overall group (n ¼ 38) was 13 days (1–60 days), with
47% (18/38) 30-day survival after device removal, 42%
(16/38) survival to discharge, and 32% (12/38) 6-month sur-
vival after device removal.
The mean duration of support for the patients supported
with a CentriMag RVAD after implantation of a commer-
cially available LVAD (n ¼ 12) was 14 days (1–29 days),
with 58% (7/12) 30-day survival after device removal,
42% (5/12) survival to discharge, and 33% (4/12) 6-month
survival after device removal. Eleven of the 12 patients in
the RVAD group underwent placement of the RVAD imme-
diately after LVAD placement, and the remaining patient
underwent placement approximately 96 hours after LVAD
placement. Of the 7 survivors in the RVAD group, 6 patients
were successfully weaned, and the remaining patient re-
ceived a long-term Thoratec RVAD (Thoratec Corporation,
Pleasanton, Calif).
The mean duration of support for the patients in the
PMICS group (n ¼ 14) was 17 days (1–60 days),
with 50% (7/14) 30-day survival after device removal,
50% (7/14) survival to discharge, and 43% (6/14) 6-month
survival after device removal. The mean duration of support
for the patients with PCCS (n¼ 12) was 8 days (1–29 days),
with 33% (4/12) 30-day survival after device removal, 33%
(4/12) survival to discharge, and 17% (2/12) 6-month sur-
vival after device removal. The 20-day postexplant survivalThe Journal of Thoracic and Cain the PCCS group was 33%, with a mean duration of
support of 8 days, as opposed to the 50% 30-day post-
explant survival of patients in the PMICS group, with
a mean duration of support of 17 days. Of the 7 survivors
in the PMICS group, 4 patients were successfully weaned,
and the remaining 3 patients were bridged to a long-term
VAD. Of the 4 survivors in the PCCS group, 3 patients
were successfully weaned, and the remaining patient was
bridged to a long-term VAD.
The mean duration of support for those patients with
biventricular CentriMag support for cardiogenic shock
(n ¼ 18) was 15 days (1–60 days), with 44% (8/18)
30-day survival after device removal. mean duration of
support for those patients with LVAD CentriMag support
for cardiogenic shock (n ¼ 8) was 8 days (1–29 days),
with 38% (3/8) 30-day survival after device removal.
Hemodynamics and End-Organ Function
Hemodynamic data are reviewed in Table 4. The central
venous pressure andmean arterial pressure, plotted as a func-
tion of days of pump implementation (1–14 days) for survi-
vors supported longer than 7 days improved during support
and remained stable throughout support. Laboratory studies
of blood urea nitrogen, creatinine, and bilirubin are shown in
Table 5. Although serum creatinine and total bilirubin re-
mained stable, there was a trend toward increased blood
urea nitrogen with time among survivors supported for
longer than 7 days.
Adverse Events
Table 6 lists all adverse events reported. As expected for
this patient population, the rates of bleeding, infection, and
respiratory failure were elevated. The number of events di-
rectly attributable to the device, however, was relatively low.
Device function and performance. Pump flow was stable
in both groups through the course of the 14-day trial, with
average flows ranging from approximately 3.5 to 6.0 L/
min. There were no instances of CentriMag system or
pump failure.
Infections. In the entire cohort (n ¼ 38), 8 patients (21%)
had 19 device-related infections. In the BVAD cohort
(n ¼ 18), 2 patients (11%) had 3 device-related infections.rdiovascular Surgery c Volume 141, Number 4 935
TABLE 4. Central venous pressure and mean arterial pressure of
survivors supported longer than 7 days
Baseline
Last value
on support After support
Right ventricular assist device group
Central venous pressure (mm Hg)
Mean  SD 17  2.7 12  7.4 14  6.9
Range 13–21 3–26 4–25
Mean arterial pressure (mm Hg)
Mean  SD 70  17.4 83  8.8 82  10.7
Range 44–93 71–96 69–94
Post–acute myocardial infarction cardiogenic shock group
Central venous pressure (mm Hg)
Mean  SD 21  10.6 17  10.6 16  10.5
Range 13–28 9–24 11–21
Mean arterial pressure (mm Hg)
Mean  SD 69  23.2 82  17.2 73  11.8
Range 51–95 64–98 66–77
Postcardiotomy cardiogenic shock group
Central venous pressure (mm Hg)
Mean  SD 13  14.8 17  5.5 18  5.5
Range 2–23 13–23 13–24
Mean arterial pressure (mm Hg)
Mean  SD 55  21.2 83  6.1 76  13.1
Range 40–70 76–88 61–86
All patients
Central venous pressure (mm Hg)
Mean  SD 16  6.7 13  7.1 15  6.1
Range 2–28 3–26 4–25
Mean arterial pressure (mm Hg)
Mean  SD 67  18.5 83  9.7 78  10.4
Range 40–95 64–98 61–94
TABLE 5. Blood urea nitrogen, creatinine, and total bilirubin in
survivors supported longer than 7 days
Baseline
Last value
on support After support
Right ventricular assist device group
Blood urea nitrogen (mg/dL)
Mean  SD 22  5.6 33  16.0 30  17.9
Range 13–30 10–59 12–62
Creatinine (mg/dL)
Mean  SD 1.5 (0.6) 1.4 (0.7) 1.5 (0.7)
Range 0.8–2.7 0.7–2.8 0.8–2.7
Total bilirubin (mg/dL)
Mean  SD 3.0 (1.7) 2.8 (2.6) 2.1 (1.5)
Range 1.0–5.2 0.5–7.7 0.6–5.0
Post–acute myocardial infarction cardiogenic shock group
Blood urea nitrogen (mg/dL)
Mean  SD 26 (18.9) 21 (6.7) 25 (9.1)
Range 11–47 13–25 18–35
Creatinine (mg/dL)
Mean  SD 1.6 (0.7) 0.9 (0.3) 1.1 (0.3)
Range 0.9–2.3 0.7–1.3 0.9–1.5
Total bilirubin (mg/dL)
Mean  SD 2.5 (2.5) 1.6 (0.1) 2.0 (0.9)
Range 1.0–5.4 1.5–1.7 1.1–2.8
Postcardiotomy cardiogenic shock group
Blood urea nitrogen (mg/dL)
Mean  SD 16 (6.4) 35 (14.4) 49 (16.5)
Range 12–23 27–52 33–66
Creatinine (mg/dL)
Mean  SD 1.0 (0.1) 0.8 (0.1) 1.4 (0.5)
Range 0.8–1.1 0.7–0.9 0.9–1.8
Total bilirubin (mg/dL)
Mean  SD 0.7 (0.3) 1.7 (1.0) 2.5 (2.0)
Range 0.5–1.0 0.5–2.5 0.5–4.4
All patients
Blood urea nitrogen (mg/dL)
Mean  SD 21 (9.8) 31 (15.2) 33 (17.4)
Range 11–47 10–59 12–66
Creatinine (mg/dL)
Mean  SD 1.4 (0.6) 1.2 (0.6) 1.4 (0.6)
Range 0.8–2.7 0.7–2.8 0.8–2.7
Total bilirubin (mg/dL)
Mean  SD 2.4 (1.8) 2.2 (2.0) 2.2 (1.4)
Range 0.5–5.4 0.5–7.7 0.5–5.0
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device-related infections.
Hemolysis. Hemolysis was considered to be device related
if it was observed beyond the first 3 days of mechanical cir-
culatory support. In the entire cohort (n ¼ 38), 2 patients
(5%) had device-related hemolysis. One patient was im-
planted with BVAD CentriMag devices for PMICS, was
successfully supported for a total of 60 days (pumps were
electively changed at day 30), and was then subsequently
successfully bridged to support with a total artificial heart.
Hemolysis was believed to have been due to cannula malpo-
sitioning. The other patient, who was also implanted with
BVAD CentriMag devices for PMICS, was effectively
supported for a total of 7 days. Support was electively termi-
nated after development of heparin-induced thrombocytope-
nia and refractory liver failure.
Thromboembolic events. Three neurologic events were
classified as ‘‘questionably related to device’’ and 1 event
was classified as device related. All events occurred in the
PCCS group. The causes of all ‘‘questionable’’ events
were indeterminate. Investigators reported risk of thrombo-
embolism for these patients as a result of inadequate antico-
agulation during weaning, intra-aortic balloon pump936 The Journal of Thoracic and Cardiovascular Surgmalfunction, or antithrombin III deficiency. The fourth
case of neurologic dysfunction occurred in a patient im-
planted with BVAD support who exhibited signs of right-
sided weakness 14 days after the implant. The investigator
considered that a possible cause of the event was embolus
from the device during a period of low flow.
DISCUSSION
Currently available circulatory support options for
patients in cardiogenic shock are known for low survivals
and the occurrence of significant complications, includingery c April 2011
TABLE 6. Adverse events
DRE type
Patients with
DREs
No. of
DREs
DREs/100 d
support
Infection 8 (21%) 19 3.8
Bleeding 2 (5%) 2 0.4
Respiratory failure 1 (3%) 1 0.2
Cardiac tamponade 1 (3%) 1 0.2
Reoperation 7 (18%) 9 1.8
Hepatic dysfunction 0 0 0
Renal failure 0 0 0
Neurologic dysfunction* 4 (11%) 4 0.8
Thrombotic, vascular 0 0 0
Thrombotic, pulmonary 0 0 0
Hemolysis 2 (5%) 5 1
Device failure 0 0 0
DRE, Device-related event. *Includes 3 events categorized as ‘‘questionably related’’
to device.
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4,5 Intra-
aortic balloon pumps and inotropic therapy have historically
been the standard of care for patients in acute cardiogenic
shock. Extracorporeal membrane oxygenation (ECMO), al-
though suitable for cardiopulmonary support in some in-
stances, does not unload the ventricles to the degree
possible with a VAD, has a high rate of device-related com-
plications, and requires that the patient be immobilized.6-8
Other commercially available extracorporeal devices have
drawbacks, such as large priming requirements, lack of
portability, limited duration of use, thromboembolic risk,
and device size.
We have demonstrated in these preliminary studies that
the CentriMag VAS is capable of providing total right and
left ventricular unloading and circulatory support for
patients with cardiogenic shock. The overall survival in
this cohort of 38 patients was 47%. Survival in the post–
myocardial infarction and RVAD after implantable LVAD
groups were 50% and 58%, respectively. Pump perfor-
mance data for the CentriMag indicated satisfactory hemo-
dynamic support sufficient to meet the patients’ circulatory
needs. The benefits associated with the CentriMag VAS in-
clude ease of implantation, adequate ventricular unloading,
reliable device function, low incidence of device-related
complications, and support conditions conducive to recov-
ery and weaning. The 6-month survival of these patients is
still relatively low, however, which strongly suggests that
improvements still can be made in the overall management
of these patients. The survival with this device is similar to
those achieved with other, previous devices, and thus these
outcomes are more related to this patient population and
patient selection than directly to the type of device.
This study highlights the need for additional data to permit
the selection of the best short-term circulatory assist system
for a patient’s condition and expected course. Comparing
survival outcomes (either survival to discharge or 30-day
postimplant survival) between single-center studies doesThe Journal of Thoracic and Canot allow a proper or accurate comparison between different
support devices, because there are many variations in patient
selection and management among centers. Until randomized
studies are performed, comparison among different thera-
peutic modalities for acute cardiogenic shock will always
have an inherent bias when based on a single center’s expe-
rience and outcomes. Nevertheless, we attempt to highlight
some studies evaluating outcomes with the different modal-
ities that provide short-term mechanical circulatory support.
The short-term VADs currently available include the
widely used ABIOMED BVS (ABIOMED, Inc, Danvers,
Mass) and Bio-Medicus systems (Medtronic) and the more
recently introduced CentriMag system. In addition, ECMO
is also a useful therapeutic modality for selected patients
in this group. More recently, percutaneous options for
short-term mechanical support have become available.
Samuels and colleagues9 reported a 31% hospital dis-
charge rate for patients with acute cardiac failure supported
by the ABIOMED BVS system. Other single centers have
also reported on their experiences with ABIOMED BVS de-
vices, with acceptable results.10,11 The advantages and
limited commercial availability of other systems have led
to an extensive experience with this system; however,
disadvantages include the need for performing
anastomoses for aortic and pulmonary artery cannulation,
with resulting bleeding complications, and the need for
pump exchanges at approximately 1-week intervals.
Even though ECMO is the best option for patients requir-
ing full cardiopulmonary support, major disadvantages in-
clude a limited duration of support, a high incidence of
complications with increasing duration of support, and the
need for fairly stringent anticoagulation. In addition,
ECMO requires a dedicated team of personnel to allow its
safe use. Pagani and associates6 of the University of Michi-
gan reported a 43% 1-year survival among patients with car-
diogenic shock either from previous cardiac arrest or severe
hemodynamic instability who were initially treated with
ECMO as a bridge to LVAD implantation. In a study from
Innsbruck, Hoefer and colleagues12 reported excellent re-
sults with ECMO support in patients with cardiogenic shock.
They reported a 50%mortality in a similar group of patients
supported by ECMO who were bridged to LVAD implanta-
tion, with most deaths due to multisystem organ failure with
sepsis. The limited durability of ECMO (the risk of compli-
cations increases with increased duration of ECMO) led to
bridging to long-term VAD support while patients still had
unresolved end-organ dysfunction during ECMO support.
More recently, there have been several encouraging publi-
cations on the use of the CentriMag for support of patients
in acute cardiogenic shock.13-15 John and coworkers14 re-
ported in a single-center study use of CentriMag support in
12 patients with refractory acute cardiogenic shock and mul-
tisystem organ failure. All patients were transferred from an
outside hospital, with a 30-day survival of 75%. The ease ofrdiovascular Surgery c Volume 141, Number 4 937
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ventricular recovery, weaning, and explantation. Its user-
friendly nature is borne out by the fact that many suitably
sized cannulas with good flow characteristics (including
those used for routine cardiopulmonary bypass) can be
successfully used. In addition, patients transferred with Bio-
Medicus centrifugal pumps had easy conversion to extracor-
poreal CentriMag support. The CentriMag’s durability is
also much greater than that of any other temporary circula-
tory assist device currently available. More recently, the
Harefield group reported greater than 80% 1-month survival
when using the Levitronix device as a bridge to decision in
critically ill patients. Remarkably, the mean duration of sup-
port was almost 50 days.15 Prolonged use of this device oc-
curred in more than 50% of cases, with the pump head
prophylactically replaced at the bedside every 28 days. Re-
cently, use of this device as a direct bridge to transplant has
been reported in selected cases, with duration of support as
long as 3 months.16 One option to consider for patients re-
quiring temporary support with the CentriMag device who
may need longer support is to design cannulas suitable for
use with long-term support devices that can be used later, if
necessary, when bridging to the long-term device.17,18
The Thoratec implantable and paracorporeal VADs are
also used for univentricular or biventricular support of pa-
tients with acute cardiogenic shock. Although these devices
are different from other short-term devices in their durabil-
ity, pulsatile flow, and potential for patient discharge, it
should be noted that they are regarded as permanent devices.
In the multicenter implantable VAD trial, support rates to
successful outcomes were 70% for bridge to transplant
and 67% for postcardiotomy recovery, versus historic re-
sults for the paracorporeal VAD trial of 69% for bridge to
transplantation and 48% for postcardiotomy recovery.19
Although many centers have reported survival with
the CentriMag device greater than that reported in this
study,13-15 it should be noted that there could be differences
in populations or a selection bias in these individual series.
In this study, despite the potential advantages of the
CentriMag VAS, the survival with this device was similar to
that achieved with other, previous devices. These outcomes
may be reflective of the patient population and selection, as
opposed to the type of device used.
The recent introduction of percutaneous VADs into the
clinical arena has provided yet another option for patients
with cardiogenic shock in select situations. In addition to
gaining popularity as temporary support during high-risk
coronary interventions, the TandemHeart (CardiacAssist
Inc, Pittsburgh, Pa) and Impella (ABIOMED) percutaneous
VADs have been successfully used for support of patients
in cardiogenic shock.20-23 Whereas their primary advantage
is the relative expediency of institution of hemodynamic
support, potential disadvantages include the limitation of
flow, thereby potentially restricting its use in larger938 The Journal of Thoracic and Cardiovascular Surgpatients. Other disadvantages include the limited duration
of support, lack of percutaneous support for the right
ventricle, possibility of cannula dislodgment and lower
extremity ischemia, the need for strict anticoagulation, and
the inability to transfer supported patients to tertiary care
centers. Relative to the percutaneous devices, the
CentriMag VAS is more versatile, because it can support
patients as a bridge to decision, bridge to transplant, or,
more commonly, bridge to permanent VAD support. The
relative disadvantage of the CentriMag VAS and other
surgically implanted temporary devices with respect to the
percutaneous devices is that the former require
a sternotomy and the need to be in a surgical operating
room (as opposed to a catheterization room) for implantation.
Although this nonrandomized, controlled clinical trial had
strict enrollment criteria and standardized definitions, there
remains a potential for variation among centers with respect
to patient management, surgical techniques, antibiotic proto-
cols, and management of postoperative complications. The
major limitations of this study were the lack of a control
group and the small number of patients studied. The overall
number of patients was relatively small and divided among 3
distinct patient populations, limiting the ability to perform
intragroup and intergroup comparisons.
CONCLUSIONS
Although major progress has been made in the selection,
mechanical support, and management of patients with
chronic end-stage heart failure with the successful introduc-
tion ofmany new and innovative implantable devices, the op-
tions and outcomes of patients supported for acute refractory
heart failure remain poor. This is mainly because of the crit-
ical condition of patients with acute cardiogenic shock but
also because of the limited availability and often delayed in-
stitution of mechanical circulatory support for this group of
patients. We have demonstrated in these preliminary studies
that the CentriMagVAS is capable of providing biventricular
support for patients with medically refractory acute cardio-
genic shock with an acceptable survival. We do not know
what the relative roles and interplay will be between surgical
and percutaneous VADs in even the near future. Until these
protocols are refined and standards of care are defined, it re-
mains imperative that we continue to be innovative, open-
minded, and aggressive in continually striving to improve
outcomes for this critically ill group of patients.
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